News | November 18, 2011

Early Studies of Using PET Scans to Predict Stroke Risk Showing Promise

November 18, 2011 – Stroke remains a major healthcare problem; it currently ranks as the third most common cause of death in Western nations, and this is only expected to increase as the population ages. For this reason, early identification of symptoms that are known predictors of stroke is a topic that was addressed with great deliberation and discussion at the 2011 VEITH symposium.

The existence of plaque in blood vessels has long been recognized as a major predictor of stroke. Because of this, it is important to have the best imaging options available to be able to fully understand the affects of plaque in the system, particularly in asymptomatic patients.

C.J. Zeebregts, M.D., Ph.D., professor of vascular surgery, department of surgery, division of vascular surgery, University Medical Center, Groningen, The Netherlands, presented important findings on advances imaging to predict risk factors of stroke associated in asymptomatic carotid plaque in patients.

 “Despite great improvements in endovascular and surgical techniques to treat carotid stenosis, there is still a clinical need for improved diagnostic imaging in order to select the right patient for the right treatment,” stated Zeebregts.

Of particular interest to Zeebregts is the use of positron emission tomography (PET) scans, a unique type of imaging that shows how the organs and tissues inside the body are actually functioning, to study the plaque in these patients. He discussed targeted clinical PET imaging tracers specific for plaque vulnerability.

In the past year, Zeebregts’ team has been working on new molecular imaging tracers to be used as a tool to identify vulnerable plaque formation with a new focus on targeted imaging. Their aim has been to find the tracer with the highest sensitivity and specificity able to determine the unstable plaque and thereby provide a powerful tool for selection of individual therapeutic strategies and monitoring the effect of interventions. The team has identified three important new tracers that may be able to fulfill this aim, and he presented these to a highly engaged audience during the VEITH symposium.

For more information: www.VEITHpress.org

 

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init